Remternetug

DB18994InvestigationalProtein Based Therapies

Remternetug is under investigation in clinical trial NCT05463731 (A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)).

Mechanism: Pharmacologically active on Amyloid-beta precursor protein and Beta amyloid plaque
Curator reviewed
Code names: LY-3372993

Resolves to

Compound

UNIIA5HTA4J6MECAS2571940-41-3

Targets

P05067APP

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Remternetug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account